Fecal Calprotectin and Phenotype Severity in Patients with Cystic Fibrosis: A Systematic Review and Meta-Analysis.
Calprotectin
Cystic fibrosis
Exocrine pancreatic insufficiency
Inflammation
Journal
Pediatric gastroenterology, hepatology & nutrition
ISSN: 2234-8646
Titre abrégé: Pediatr Gastroenterol Hepatol Nutr
Pays: Korea (South)
ID NLM: 101590471
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
04
08
2021
accepted:
11
10
2021
entrez:
28
1
2022
pubmed:
29
1
2022
medline:
29
1
2022
Statut:
ppublish
Résumé
Inflammation plays an important role in the outcome of patients with cystic fibrosis (CF). It may develop due to cystic fibrosis transmembrane conductance regulator protein dysfunction, pancreatic insufficiency, or prolonged pulmonary infection. Fecal calprotectin (FC) has been used as a noninvasive method to detect inflammation. Therefore, the aim of the current meta-analysis was to investigate the relationship between FC and phenotype severity in patients with CF. In this study, searches were conducted in PubMed, Science Direct, Scopus, and Embase databases up to August 2021 using terms such as "cystic fibrosis," "intestine," "calprotectin," and "inflammation." Only articles published in English and human studies were selected. The primary outcome was the level of FC in patients with CF. The secondary outcome was the relationship between FC and clinical severity. Statistical analysis was performed using Comprehensive Meta-Analysis software. Of the initial 303 references, only six articles met the inclusion criteria. The mean (95% confidence interval [CI]) level of FC was 256.5 mg/dL (114.1-398.9). FC levels were significantly associated with pancreatic insufficiency (mean, 243.02; 95% CI, 74.3 to 411.6;
Identifiants
pubmed: 35087728
doi: 10.5223/pghn.2022.25.1.1
pmc: PMC8762598
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1-12Informations de copyright
Copyright © 2022 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition.
Déclaration de conflit d'intérêts
Conflict of Interest: The authors have no financial conflicts of interest.
Références
J Pediatr Gastroenterol Nutr. 2015 Apr;60(4):521-6
pubmed: 25539196
J Pediatr Gastroenterol Nutr. 2010 Sep;51(3):304-8
pubmed: 20512061
J Cyst Fibros. 2017 Nov;16 Suppl 2:S14-S23
pubmed: 28986022
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
J Pediatr Gastroenterol Nutr. 2019 Feb;68(2):282-284
pubmed: 30640865
J Cyst Fibros. 2018 Jan;17(1):109-113
pubmed: 28754328
Future Sci OA. 2015 Sep 01;1(2):FSO57
pubmed: 28031875
Sci Rep. 2019 Dec 9;9(1):18593
pubmed: 31819107
Nat Rev Immunol. 2014 Dec;14(12):827-35
pubmed: 25421702
Curr Mol Med. 2010 Feb;10(1):82-94
pubmed: 20205681
J Pediatr. 1992 May;120(5):696-701
pubmed: 1578303
Clin Biochem. 2012 Oct;45(15):1132-44
pubmed: 22698459
J Cyst Fibros. 2017 Sep;16(5):631-636
pubmed: 28416415
Infect Immun. 2004 Oct;72(10):6040-9
pubmed: 15385508
Gastroenterol Hepatol (N Y). 2016 Jan;12(1):43-7
pubmed: 27330503
J Inflamm Res. 2010;3:61-74
pubmed: 22096358
Prz Gastroenterol. 2017;12(1):38-43
pubmed: 28337235
PLoS One. 2020 May 8;15(5):e0232685
pubmed: 32384122
J Cyst Fibros. 2019 Jan;18(1):13-21
pubmed: 30487080
Pediatr Pulmonol. 2018 Nov;53(S3):S30-S50
pubmed: 29999593
PLoS One. 2015 Oct 20;10(10):e0138062
pubmed: 26484665
PLoS One. 2018 Jun 22;13(6):e0198457
pubmed: 29933382
Immunobiology. 2017 Mar;222(3):582-586
pubmed: 28012584
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
J Cyst Fibros. 2015 Jul;14(4):419-30
pubmed: 25814049
Clin Microbiol Infect. 2014 Feb;20(2):123-9
pubmed: 24320992
J Cyst Fibros. 2017 Mar;16(2):186-197
pubmed: 27693010
J Pediatr Gastroenterol Nutr. 2017 Oct;65(4):438-442
pubmed: 28207476
Arch Dis Child. 2001 Apr;84(4):374-5
pubmed: 11280349
J Pediatr. 2015 Jul;167(1):138-47.e1-3
pubmed: 25818499
Gut. 1993 Oct;34(10):1357-63
pubmed: 8244101
BMC Pediatr. 2014 May 29;14:133
pubmed: 24885444
PLoS One. 2014 Feb 19;9(2):e87796
pubmed: 24586292
Int J Surg. 2010;8(5):336-41
pubmed: 20171303